December 1, 2020

US Bioservices now dispenses ENSPRYNG™ (satralizumab-mwge)

ENSPRYNG™ (satralizumab-mwge) is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.